KLF4:一个连接瘤进展和免疫调节的多功能关节
Yunjie Ju1, Wen Xiao1, Bryan James Mathis2
1Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
克鲁佩尔样因子4 (KLF4) 在癌症中具有双重作用,既起瘤促进作用,又起瘤抑制作用. 它的过度表达通过促进CD8+T细胞分化来增强抗瘤免疫力.
科学领域:
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 克鲁佩尔样因子 (KLF) 是调节关键细胞过程的转录因子.
- KLF4在瘤发生中的作用取决于情境,影响炎症和免疫反应.
- KLF4可以作为瘤促进剂或瘤抑制剂.
研究的目的:
- 审查KLF4,免疫力和癌症之间的复杂关系.
- 阐明KLF4在各种瘤类型和阶段的多方面的作用.
- 为未来的KLF4介导癌症免疫研究方向提供见解.
主要方法:
- 文献综述和对KLF4.4现有研究的综合.
- 在不同癌症背景下分析KLF4的功能.
- 检查KLF4对免疫细胞分化和功能的影响.
主要成果:
- KLF4在癌症发育中表现出特定于背景的功能.
- KLF4 影响了前瘤和抗瘤路径.
- 过度表达KLF4促进CD8+T细胞分化,增强抗瘤免疫力.
结论:
- KLF4在免疫和癌症中的复杂作用需要进一步研究.
- 了解KLF4的双重功能对于开发新型癌症免疫疗法至关重要.
- 准KLF4通路可能为癌症治疗提供新的治疗策略.
更多相关视频
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
07:44Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
相关概念视频
Tumor Immunotherapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
The Tumor Microenvironment
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
